Table 5 Soluble PRR, renin, and prorenin in plasma and urine distributed by type of anti-hypertensive treatment

  sPRR (ng/mL)

16.6 ± 4.1

17.3 ± 6.4

21.8 ± 9.8*

18.1 ± 4.3

23.3 ± 7.0

20.0 ± 8.6

11.9

22.7 ± 4.1

  Renin activity (ng Ang-I/mL/h)

3.3 ± 0.3

13.2 ± 2.0*

17.1 ± 1.7*

11.8 ± 1.7*

5.4 ± 1.2

10.0 ± 1.7*

21.12

7.5 ± 5.5

 Urine

  sPRR/uCr (ng/mg)

16 ± 1.6

0.95 ± 0.8

0.90 ± 0.8

0.81 ± 0.9

0.40 ± 0.2

1.0 ± 1.4

115

0.91 ± 0.5

  Renin activity (ng Ang-I/mL/h)

26.9 ± 36

102.1 ± 102*

51.46 ± 44*

96.89 ± 105*

221.1 ± 182*

102.2 ± 73*

273.8

50.12 ± 23*

  Prorenin/uCr (ng/g)

142.1 ± 159

270.7 ± 326

346.5 ± 281.8

275.5 ± 236.1

113.0 ± 12.87

357 ± 336*

1075

202 ± 148

Men, n

69

10

5

12

3

11

0

0

 Plasma

  sPRR (ng/mL)

18 ± 4.7

16.3 ± 5.0

17.4 ± 4.8

18.2 ± 4.7

25.4 ± 7.0

17.0 ± 6.2

–

–

  Renin activity (ng Ang-I/mL/h)

3.2 ± 3.6

13.2 ± 12*

4.2 (n = 1)

9.3 ± 7.1^†

4.9 ± 2.8

6.5 ± 3.3

–

–

 Urine

  sPRR/uCr (ng/mg)

1.4 ± 1.2

0.78 ± 0.8

0.4 ± 0.5

0.65 ± 0.5

0.36 ± 0.25

0.65 ± 0.5

–

–

  Renin activity (ng Ang-I/mL/h)

15 ± 17.6

131.5 ± 1.4*

28.41 (n = 1)

108 ± 107*

308 ± 142*^†

105.8 ± 52*

–

–

  Prorenin/uCr (ng/g)

120 ± 97.2

380 ± 0.4

953.5 (n = 1)

215 ± 156

113 ± 12.9^‡

520.2 ± 388*

–

–

Women, n

99

15

8

18

1

8

1

4

 Plasma

  sPRR (ng/mL)

15.5 ± 3.3

17.8 ± 7.3

24.5 ± 11.3*^†

18.1 ± 4.2

17.2

23.8 ± 10*^†

12

22.7 ± 4.2

  Renin activity (ng Ang-I/mL/h)

2.8 ± 2.4

13.2 ± 8.0*

18.8 ± 1.9*

13.3 ± 8.4*

6.4

11.1 ± 6.4*

21.12

7.5 ± 9.7^‡

 Urine

  sPRR/uCr (ng/mg)

0.95 ± 0.08

0.86 ± 0.1

1.2 ± 0.1

0.49 ± 0.1

0.53

1.5 ± 0.2

0.11

0.780 ± 0.61

  Renin activity (ng Ang-I/mL/h)

19.5 ± 22

84 ± 68*

54 ± 45

67.6 ± 50*

46

97.6 ± 98*

273

50.1 ± 23

  Prorenin/uCr (ng/g)

99.4 ± 84.7

207 ± 198

260 ± 150

312.3 ± 271*

–

193.4 ± 180

1075

202 ± 147